MJFF’s flagship study, the Parkinson’s Progression Markers Initiative (PPMI), unveils scientific discoveries and research findings at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) on September 27 – October 1, highlighting the latest advances in Parkinson’s disease biomarkers and treatments.
PPMI lead investigators will present 24 posters at the MDS conference. These presentations offer a deep dive into critical research findings, from biomarkers to machine learning and wearable sensors. By shedding light on emerging insights into Parkinson’s disease progression, these posters underscore the groundbreaking work shaping the future of clinical trials and treatments.
For instance, Bridget McMahon, RN, BSN, CCRC, will discuss “Investigating Biomarker Driven PD progression,” highlighting the importance of PPMI participants and their data on biomarker discovery. Laura Heathers, BA, CCRP, will present on “Centralizing brain tissue donation for a large multi-site Parkinson’s disease study". Michael Brumm will report for the first time data on the longitudinal change in NSD- ISS in the PPMI cohort and Paulina Gonzalez Latapi will present 10 year data on the longitudinal change in individuals with sporadic PD who meet NSD criteria. Additionally, Ethan Brown, MD, explores scalable study participation and early detection in a poster titled “Remote recruitment of hyposmic participants identifies biomarkers related to neuronal alpha-synuclein disease.”